EGFR and neoplasm: In light of this, the EGFR mutation profile in NSCLC patients should be determined quickly, given that the early detection of circulating EGFR mutations in plasma, as well as increasing mutation levels, is prognostic of rapid tumor progression, and should signal the opportunity to consider transitioning to a different treatment.